Overview

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry

Status:
Completed

Trial end date:
2019-07-02

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the effect of linagliptin 5 mg daily versus the corresponding placebo on the LV systolic function (measured by midwall shortening analysis) in patients with T2DM and a documented baseline concentric LV geometry and LV systolic dysfunction.

Phase:

Phase 3

Details

Lead Sponsor:

Heart Care Foundation

Collaborators:

Fondazione dell'Associazione Medici Diabetologi
Fondazione dell’Associazione Medici Diabetologi

Treatments:

Dipeptidyl-Peptidase IV Inhibitors
Linagliptin